Why An AI Biotech Startup Launched A $600 Million Fund To Buy Stalled Drugs

Fecha de publicación: 28 de octubre de 2026, 13:00

Most AI drug development firms are focused on discovery. AI biotech Formation Bio is betting the real bottleneck is clinical trials. With a new $600 million fund to buy or license potential drugs that have stalled out, the startup now hopes to prove that it’s right.